EcoDrugPlus

Opioid Receptor, Mu 1

Ensembl ID : ENSDLAG00005020527
Gene Symbol: OPRM1
1 Cross references
215 Possible Orthologues:

Oxytocin Receptor A

Ensembl ID : ENSDLAG00005031803
Gene Symbol: OXTRA
1 Cross references
193 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSDLAG00005028827
Gene Symbol: PTH1R
1 Cross references
198 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSDLAG00005006757
Gene Symbol: PPARG
1 Cross references
389 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha A

Ensembl ID : ENSDLAG00005028792
Gene Symbol: PPARAA
1 Cross references
384 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha B

Ensembl ID : ENSDLAG00005022318
Gene Symbol: PPARAB
1 Cross references
397 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Delta B

Ensembl ID : ENSDLAG00005013901
Gene Symbol: PPARDB
1 Cross references
392 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSDLAG00005020770
Gene Symbol: PIK3CB
1 Cross references
217 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Delta

Ensembl ID : ENSDLAG00005023018
Gene Symbol: PIK3CD
1 Cross references
214 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSDLAG00005006696
Gene Symbol: PDE10A
1 Cross references
207 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSDLAG00005019494
Gene Symbol: PDE3A
1 Cross references
185 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSDLAG00005017137
Gene Symbol: PDE3B
1 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).